Obesity is linked to a heightened risk of developing triple-negative breast cancer (TNBC).
Obesity-associated triple-negative breast cancer (OA-TNBC) presents limited therapeutic options and is characterized by a poor prognosis.
Although Astragaloside IV (ASIV) exhibits anti-tumor properties across different cancers, its effect and mechanisms in OA-TNBC remain unclear.
